Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc.（IOVA）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · IOVA · 截至 2025年9月30日
股东结构概览
263
机构持有人数
▲ 6 vs Q2
$462.29M
机构持仓总市值
▲ $82.99M vs Q2
357.53M
总流通股
freeFloat 83.86%
213.04M
13F 申报持股数
▼ 7.25M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
IOVA 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
MHR FUND MANAGEMENT LLC biological products, (no diagnostic substances) | 28.97M | 8.66% | 8.66% | $62.86B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 25.96M | 7.76% | 7.76% | $56.33B | Nov 12, 2025 | ▲ 2.72M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 24.06M | 7.19% | 7.19% | $52.21B | Nov 7, 2025 | ▼ 1.02M |
STATE STREET CORP biological products, (no diagnostic substances) | 13.31M | 3.98% | 3.98% | $28.88B | Nov 14, 2025 | ▲ 3.42M |
INVENOMIC CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 10.54M | 3.15% | 3.15% | $22.88B | Nov 14, 2025 | ▲ 2.25M |
LONG FOCUS CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 9.12M | 2.73% | 2.73% | $19.78B | Nov 14, 2025 | ▼ 2.70M |
PALO ALTO INVESTORS LP biological products, (no diagnostic substances) | 7.62M | 2.28% | 2.28% | $16.53B | Nov 14, 2025 | ▲ 4.19M |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 6.87M | 2.05% | 2.05% | $14.91B | Nov 12, 2025 | ▲ 679.2K |
GOLDMAN SACHS GROUP INC biological products, (no diagnostic substances) | 6.58M | 1.97% | 1.97% | $14.27B | Nov 14, 2025 | ▲ 1.83M |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 6.28M | 1.88% | 1.88% | $13.63B | Feb 3, 2026 | ▲ 2.25M |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
24
增持
+23.23M 股1
新建仓
首次建仓19
减持
−21.19M 股0
清仓
完全退出净股数变化（前50家）
+2.04M
+23.23M / −21.19M
净新增持仓人
+6
新建 1 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
IOVA 内幕交易记录
数据来源：SEC Form 4
1
买入笔数
2
卖出笔数
0.50
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Vogt Frederick G Interim CEO & General Counsel | Jun 1, 2026 | Tax Withhold | 17,701 | $3.96 | $70.1K | 553.5K | Form 4 ↗ |
Puri Raj K. Chief Regulatory Officer | Jun 1, 2026 | Tax Withhold | 2,508 | $3.96 | $9.9K | 242.2K | Form 4 ↗ |
GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Jun 1, 2026 | Tax Withhold | 4,473 | $3.96 | $17.7K | 136.3K | Form 4 ↗ |
BILINSKY IGOR Chief Operating Officer | Jun 1, 2026 | Tax Withhold | 4,473 | $3.96 | $17.7K | 130.1K | Form 4 ↗ |
Kirby Daniel Gordon Chief Commercial Officer | May 11, 2026 | Tax Withhold | 2,435 | $3.70 | $9.0K | 146.9K | Form 4 ↗ |
Roche Corleen M. Chief Financial Officer | Mar 9, 2026 | Award | 132,200 | — | — | 132.2K | Form 4 ↗ |
Vogt Frederick G Interim CEO & General Counsel | Mar 9, 2026 | Award | 235,000 | — | — | 235.0K | Form 4 ↗ |
Puri Raj K. Chief Regulatory Officer | Mar 9, 2026 | Award | 117,500 | — | — | 117.5K | Form 4 ↗ |
GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Mar 9, 2026 | Award | 58,750 | — | — | 58.8K | Form 4 ↗ |
Kirby Daniel Gordon Chief Commercial Officer | Mar 9, 2026 | Award | 132,200 | — | — | 132.2K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Iovance Biotherapeutics, Inc.（IOVA）主要由机构投资者持有，机构持股比例约为 59.6%。公司内部人员持股约 16.14%，散户及公众持股约占剩余的 24.28%。
Iovance Biotherapeutics, Inc. 最大机构股东为 MHR FUND MANAGEMENT LLC，截至 September 30, 2025 持有约 28.97 million 股，占总流通股的 8.66%。
目前共有 263 家机构持有 IOVA 股票，合计持仓市值约 $462,294,782，数据来源为最新 SEC 13F 申报。
常见问题
IOVA ownershipIovance Biotherapeutics, Inc.（IOVA）主要由机构投资者持有，机构持股约 59.6%。最大股东为 MHR FUND MANAGEMENT LLC，持股比例 8.66%。内部人员持股约 16.14%。数据来源 SEC Form 13F，截至 September 30, 2025。